269. Pyogenic arthritis Clinical trials / Disease details
Clinical trials : 23 / Drugs : 30 - (DrugBank : 12) / Drug target genes : 15 - Drug target pathways : 106
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01302795 (ClinicalTrials.gov) | February 2011 | 17/2/2011 | Canakinumab for Pyoderma Gangrenosum | A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: Canakinumab | University of Zurich | NULL | Completed | 18 Years | 99 Years | Both | 5 | Phase 2 | Switzerland |